ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 001,80
-0,48%
Dow Jones
38 798,99
-0,22%
DAX
18 557,27
-0,48%
Brent Oil
79,395
0,00%
Bitcoin
69 296,80
-0,05%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Kymera Therapeutics Inc (KYMR)

  7. Kymera Therapeutics Inc (KYMR) Actualités

KYMR

Kymera Therapeutics (KYMR)

Kymera Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:KYMR
DateHeureSourceTitreSymboleSociété
01/06/202414h00GlobeNewswire Inc.Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual MeetingNASDAQ:KYMRKymera Therapeutics Inc
29/05/202413h00GlobeNewswire Inc.Kymera Therapeutics to Participate in Upcoming June Investor ConferencesNASDAQ:KYMRKymera Therapeutics Inc
23/05/202423h00GlobeNewswire Inc.Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual MeetingNASDAQ:KYMRKymera Therapeutics Inc
22/05/202417h20GlobeNewswire Inc.Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual MeetingNASDAQ:KYMRKymera Therapeutics Inc
14/05/202416h00GlobeNewswire Inc.Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual MeetingNASDAQ:KYMRKymera Therapeutics Inc
08/05/202413h00GlobeNewswire Inc.Kymera Therapeutics to Participate in Upcoming May Investor ConferencesNASDAQ:KYMRKymera Therapeutics Inc
02/05/202413h00GlobeNewswire Inc.Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business UpdateNASDAQ:KYMRKymera Therapeutics Inc
25/04/202413h00GlobeNewswire Inc.Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2NASDAQ:KYMRKymera Therapeutics Inc
08/04/202413h00GlobeNewswire Inc.Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual MeetingNASDAQ:KYMRKymera Therapeutics Inc
08/03/202416h00GlobeNewswire Inc.Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual MeetingNASDAQ:KYMRKymera Therapeutics Inc
05/03/202400h21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KYMRKymera Therapeutics Inc
04/03/202423h50Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:KYMRKymera Therapeutics Inc
28/02/202413h00GlobeNewswire Inc.Kymera Therapeutics to Participate in Upcoming March Investor ConferencesNASDAQ:KYMRKymera Therapeutics Inc
22/02/202413h32Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:KYMRKymera Therapeutics Inc
22/02/202413h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KYMRKymera Therapeutics Inc
22/02/202413h00GlobeNewswire Inc.Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business UpdateNASDAQ:KYMRKymera Therapeutics Inc
15/02/202413h00GlobeNewswire Inc.Kymera Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 22NASDAQ:KYMRKymera Therapeutics Inc
31/01/202413h00GlobeNewswire Inc.Kymera Therapeutics to Present in Fireside Chat at the Guggenheim Healthcare ConferenceNASDAQ:KYMRKymera Therapeutics Inc
09/01/202415h17GlobeNewswire Inc.Kymera Therapeutics Outlines Key 2024 Objectives and Strategy to Progress Leading Portfolio of Immunology and Oncology ProgramsNASDAQ:KYMRKymera Therapeutics Inc
09/01/202415h15GlobeNewswire Inc.Kymera Therapeutics Announces Closing of Upsized $275 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesNASDAQ:KYMRKymera Therapeutics Inc
05/01/202422h02Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:KYMRKymera Therapeutics Inc
05/01/202412h00GlobeNewswire Inc.Kymera Therapeutics Announces Pricing of $275 Million Public OfferingNASDAQ:KYMRKymera Therapeutics Inc
04/01/202422h01GlobeNewswire Inc.Kymera Therapeutics Announces Proposed Public OfferingNASDAQ:KYMRKymera Therapeutics Inc
04/01/202413h00GlobeNewswire Inc.R&D Day Highlights Kymera’s Immunology Strategy and Emerging Pipeline of Novel, First-in-Class Oral Degraders Addressing Multiple Highly Prevalent Immuno-inflammatory DiseasesNASDAQ:KYMRKymera Therapeutics Inc
02/01/202413h00GlobeNewswire Inc.Kymera Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024NASDAQ:KYMRKymera Therapeutics Inc
13/12/202313h00GlobeNewswire Inc.Kymera Therapeutics to Host Virtual Immunology R&D Day on January 4NASDAQ:KYMRKymera Therapeutics Inc
11/12/202303h00GlobeNewswire Inc.Kymera Therapeutics Presents Interim Results from STAT3 Degrader Phase 1 Clinical Trial at American Society of Hematology Annual MeetingNASDAQ:KYMRKymera Therapeutics Inc
07/12/202313h00GlobeNewswire Inc.Kymera Therapeutics Announces First Patient Dosed in Phase 2 Atopic Dermatitis Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating a $15 Million Payment from SanofiNASDAQ:KYMRKymera Therapeutics Inc
13/11/202317h00GlobeNewswire Inc.Kymera Therapeutics Announces Publication of Phase 1 Trial Results for KT-474 (SAR444656), a First-in-Class IRAK4 Degrader, in Nature MedicineNASDAQ:KYMRKymera Therapeutics Inc
02/11/202314h00GlobeNewswire Inc.Kymera Therapeutics to Present New Clinical Data from the Phase 1 Trial of STAT3 Degrader KT-333 at the ASH Annual MeetingNASDAQ:KYMRKymera Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:KYMR

Dernières Valeurs Consultées

EU
BN
Danone
EU
AI
Air Liquide
NYSE
MRK
Merck
USI
USTECH100
US Tech 100
NYSE
JPM
JP Morgan Chase
EU
HO
Thales
EU
RNO
Renault
EU
MC
Lvmh Moet Hennessy Louis...
EU
ML
Michelin
EU
PX1
CAC 40
NASDAQ
AAPL
Apple
NYSE
NKE
Nike
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés